坤泰胶囊联合米非司酮治疗子宫肌瘤的疗效分析

目的 研究坤泰胶囊联合米非司酮治疗子宫肌瘤的临床疗效。方法 选取2018年6月-2020年6月北京市通州区妇幼保健院收治的106例子宫肌瘤患者为研究对象，将患者按照治疗方法分为对照组和观察组，每组各53例。对照组从月经周期第1天开始服用米非司酮片，12.5 mg/次，1次/d；观察组在对照组治疗基础上服用坤泰胶囊，4粒/次，3次/d。两组连续治疗3个月。观察两组患者的临床疗效，比较治疗前后患者的子宫肌瘤及子宫体积、性激素水平、不良反应发生情况以及复发率。结果 治疗后，观察组总有效率为98.11%，高于对照组的90.56%，差异具有统计学意义（P<0.05）。治疗后，两组患者子宫肌瘤及子宫积与治疗前相比均有所缩小（P<0.05）；观察组患者的子宫肌瘤及子宫积显著小于对照组（P<0.05）。治疗后，两组促卵泡生成素、孕酮、雌二醇和促黄体生成素水平均显著下降（P<0.05）；观察组治疗后激素水平明显低于对照组（P<0.05）。治疗过程中，观察组不良反应总发生率低于对照组（P<0.05）；治疗后半年内，观察组子宫肌瘤复发率为1.89%，低于对照组的9.43%，差异具有统计学意义（P<0.05）。结论 坤泰胶囊联合米非司酮联合治疗子宫肌瘤的疗效显著，有助于促进子宫肌瘤缩小，降低性激素水平，并能降低复发率，且用药安全性高，值得推广应用。

Efficacy of Kuntai Capsules combined with mifepristone in treatment of uterine fibroids

Objective To study the clinical effect of Kuntai Capsules combined with mifepristone in treatment of uterine fibroids. Methods A total of 106 patients with uterine fibroids admitted to Tongzhou Maternal & Child Health Hospital of Beijing from June 2018 to June 2020 were selected as the research subjects, and the patients were divided into control group and observation group according to treatment methods, with 53 cases in each group. Patients in the control group were po administered with Mifepristone Tablets 12.5 mg/time, once daily from the first day of menstrual cycle. Patients in the observation group were po administered with Kuntai Capsules on the basis of control group, four grains/time, three times daily. Two groups were treated for three months. Clinical efficacy of two groups was observed, and uterine fibroids, uterine volume, sex hormone levels, the incidence of adverse reactions, and recurrence rate of patients before and after treatment were compared. Results After treatment, the total effective rate of the observation group was 98.11%, which was higher than 90.56% of the control group, and the difference was statistically significant (P<0.05). After treatment, uterine fibroids and uterine volume in two groups were reduced compared with before treatment (P<0.05). The uterine fibroids and uterine volume in observation group were significantly lower than those in control group (P<0.05). After treatment, the levels of follicle stimulating hormone, progesterone, estradiol and luteinizing hormone in two groups were significantly decreased (P<0.05). The hormone level of observation group was significantly lower than control group after treatment (P<0.05). During treatment, the total incidence of ADR in observation group was lower than that in control group (P<0.05). Within half a year after treatment, the recurrence rate of uterine fibroids in the observation group was 1.89%, lower than 9.43% in the control group, and the difference was statistically significant (P<0.05). Conclusion Kuntai Capsules combined with mifepristone has a significant therapeutic effect on uterine fibroids, which is helpful to promote the reduction of uterine fibroids, reduce the level of sex hormones, and reduce the recurrence rate. Moreover, it has high safety and is worthy of popularization and application.